Heart Failure Connect
  • Saved

2yr
Effects of Semaglutide on Symptoms, Function, and Quality of Life in Patients With Heart Failure With Preserved Ejection Fraction and Obesity: a Prespecified Analysis of the STEP-HFpEF Trial

Effects of Semaglutide on Symptoms, Function, and Quality of Life in Patients With Heart Failure With Preserved Ejection Fraction and Obesity: a Prespecified Analysis of the STEP-HFpEF Trial

Source : https://pubmed.ncbi.nlm.nih.gov/37952180/

Patients with heart failure (HF) with preserved ejection fraction (HFpEF) and obesity experience high burden of symptoms and functional impairment, and a poor quality of life.

  • Saved

2yr
Rethinking the Impact and Management of Diabetes in Heart Failure Patients

Rethinking the Impact and Management of Diabetes in Heart Failure Patients

Source : https://link.springer.com/article/10.1007/s11897-023-00633-x

The following overview article summarizes the most important aspects of diagnosis and screening and provides an overview on the current evidence of glucose-lowering and heart failure treatment in patients with...

Given the increasing incidence of diabetes and heart failure as well as the impaired prognosis if both comorbidities come together, treatment of these patients requires an interdisciplinary, evidence-based approach to reduce morbidity and mortality in this high-risk population.

  • Saved

2yr
Cardiovascular death and hospitalization in patients with heart failure

The incidence and prevalence of heart failure (HF) has increased in recent years. Experts suggest that this increase in frequency may be due to the growing elderly population with comorbidities such as hypertension and T2DM. Another reason why the number of HF patients has risen could be due to longer survival in those individuals with the condition. HF is a leading cause of hospitalizations, and recurrent HF hospitalization (hFH) predicts cardiovascular (CV) and all-cause mortality. 

In a recent meta-analysis, investigators mined data from various trials, which are grouped by HF presentation as follows:

•Patients with HF with mid-range ejection fraction (HFmrEF) or HF with preserved ejection fraction (HFpEF)

-DELIVER trial (dapagliflozin)

-EMPEROR-Preserved trial (empagliflozin)

•Patients with HF with reduced ejection fraction (HFrEF)

-DAPA-HF trial (dapagliflozin)

-EMPEROR-Reduced trial (empagliflozin)

•Patients with worsening HF regardless of ejection fraction

-SOLOIST-WHF trial (sotagliflozin)

The aim of this meta-analysis was to gauge the effects of SGLT2 inhibitors on different clinical outcomes of heart failure. 

In the trials assessed (n=21,947), SGLT2 inhibitors decreased the risk of composite cardiovascular death or hospitalization for heart failure (HR: 0.77); cardiovascular death (HR: 0.87); first hospitalization for heart failure (HR: 0.72); and all-cause mortality (HR: 0.92) Overall, this meta-analysis demonstrated that SGLT2 inhibitors decreased the risk of cardiovascular death and hospitalizations for heart failure in a broad gamut of heart-failure presentations, thus bolstering their role as foundational therapy for heart failure—regardless of ejection fraction.

What have you found to be effective in reducing the risk of heart-failure hospitalization in your HF patients?

  • 2yr
    SGLT2 Inhibitors now play an important role in reducing the risk of hospitalization in heart failure patients. Optimal guideline-directed medical therapy is also essential utilizing ACE/ARB/ARNI, diuretics, beta-blockers, Show More
  • 2yr
    Both systolic and diastolic heart failure have unacceptably high mortality. The introduction of drugs like empa, dapa may well improve these high rates. If one considers soloist, rugs like Impefa Show More

Show More Comments

  • Saved

2yr
Major Adverse Cardiovascular Events of Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitors Among Patients With Different Malignancy: a Systemic Review and Network Meta-Analysis

Major Adverse Cardiovascular Events of Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitors Among Patients With Different Malignancy: a Systemic Review and Network Meta-Analysis

Source : https://journals.lww.com/jcma/abstract/9900/major_adverse_cardiovascular_events_of_vascular.304.aspx

We searched PubMed, Embase, and ClinicalTrials.gov from inception until August 31, 2021, for phase II/III randomized controlled trials of 11 VEGF-TKIs (axitinib, cabozantinib, lenvatinib, pazopanib, ponatinib, ripretinib, regorafenib, sorafenib, sunitinib,...

The risk of heart failure significantly increased in association with less selective sorafenib (OR: 3.53), pazopanib (OR: 3.10), and sunitinib (OR: 2.65).

  • Saved

2yr
Cardiovascular and Renal Benefit of Novel Non-Steroidal Mineralocorticoid Antagonists in Patients with Diabetes

Cardiovascular and Renal Benefit of Novel Non-Steroidal Mineralocorticoid Antagonists in Patients with Diabetes

Source : https://link.springer.com/article/10.1007/s11886-023-01998-0

Novel non-steroidal mineralocorticoid receptor (MR) antagonists (MRAs) are a new class of drugs blocking adverse MR-mediated effects with an improved benefit-risk profile compared to steroidal MRAs. This review will provide...

This review provide information’s on the preclinical and clinical pharmacology of this new drug class and will discuss its future clinical applications in patients with cardiorenal disease.